18.97.9.175
dgid:
enl:
npi:0
-Advertisement-
Home PHOTON trial assesses aflibercept 8 mg for diabetic macular edema

Diabetic Macular Edema

PHOTON trial assesses aflibercept 8 mg for diabetic macular edema

Watch Now
By rd360stg
Modeling study observes extended durability of aflibercept 8 mg
By rd360stg
Long-term costs of diabetic macular edema significantly exceed those of diabetes alone
By rd360stg
Study finds age impacts effectiveness of anti-VEGF treatments for diabetic macular edema
By rd360stg
Study finds optimal timing for steroid switch in DME treatment
-Advertisement-
-Advertisement-
-Advertisement-
By rd360stg
Faricimab matches aflibercept in VA improvement, outperforms in reducing retinal thickness for DME
By rd360stg
Study: Similar results in DEXI behavior in DME patients with various prior treatments
By rd360stg
Laser combination therapy not significantly more effective for anti-VEGF-resistant DME than anti-VEGF monotherapy
By rd360stg
Faricimab shows sustained efficacy in diabetic macular edema treatment
-Advertisement-
-Advertisement-
-Advertisement-
By rd360stg
Early intravitreal corticosteroids for diabetic macular edema gain momentum
By rd360stg
Anti-VEGF treatment effect patients’ social and emotional well-being
By rd360stg
Brolucizumab is safe, effective in diabetic macular edema
By rd360stg
Positive results from Phase 2 trial of ABBV-RGX-314 for diabetic retinopathy presented at AAO 2023
-Advertisement-
-Advertisement-
Videos
All
PHOTON trial assesses aflibercept 8 mg for diabetic macular edema
31 Oct, 2024

Sean Adrean, MD, of Retina Consultants of Orange County, discusses...

Modeling study observes extended durability of aflibercept 8 mg
30 Oct, 2024
-Advertisement-
-Advertisement-

Contact Info

Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809

+908-505-8899
[email protected]

Social Links

© 2024 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved
-Advertisement-
-Advertisement-